In vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile.
The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).
Fasola
E L
EL
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55417.
Moody
J A
JA
Gerding
D N
DN
Peterson
L R
LR
D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology; D001798:Blood Proteins / Q000378:metabolism; D016360:Clostridioides difficile / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D016106:Methicillin Resistance; D013211:Staphylococcus aureus / Q000187:drug effects / Q000378:metabolism*; D014640:Vancomycin / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; C057893:chloroorienticin A; D014640:Vancomycin